KR102823195B1 - Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 - Google Patents

Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 Download PDF

Info

Publication number
KR102823195B1
KR102823195B1 KR1020207034544A KR20207034544A KR102823195B1 KR 102823195 B1 KR102823195 B1 KR 102823195B1 KR 1020207034544 A KR1020207034544 A KR 1020207034544A KR 20207034544 A KR20207034544 A KR 20207034544A KR 102823195 B1 KR102823195 B1 KR 102823195B1
Authority
KR
South Korea
Prior art keywords
compound
group
groups
ring
chemical formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034544A
Other languages
English (en)
Korean (ko)
Other versions
KR20210006407A (ko
Inventor
아이합 다위시
쟈신 위
얀 천
에스테반 마스다
바네사 테일러
Original Assignee
리겔 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리겔 파마슈티칼스, 인크. filed Critical 리겔 파마슈티칼스, 인크.
Publication of KR20210006407A publication Critical patent/KR20210006407A/ko
Application granted granted Critical
Publication of KR102823195B1 publication Critical patent/KR102823195B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207034544A 2018-05-03 2019-05-02 Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 Active KR102823195B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666452P 2018-05-03 2018-05-03
US62/666,452 2018-05-03
PCT/US2019/030473 WO2019213445A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (2)

Publication Number Publication Date
KR20210006407A KR20210006407A (ko) 2021-01-18
KR102823195B1 true KR102823195B1 (ko) 2025-06-20

Family

ID=66554488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034544A Active KR102823195B1 (ko) 2018-05-03 2019-05-02 Rip1 억제 화합물 및 이를 제조하고 사용하는 방법

Country Status (38)

Country Link
US (3) US10975064B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788045B1 (cg-RX-API-DMAC7.html)
JP (1) JP7379467B2 (cg-RX-API-DMAC7.html)
KR (1) KR102823195B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384510B (cg-RX-API-DMAC7.html)
AU (1) AU2019262142B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002840A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015153A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200582A (cg-RX-API-DMAC7.html)
CY (1) CY1126152T1 (cg-RX-API-DMAC7.html)
DK (1) DK3788045T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2020000197A (cg-RX-API-DMAC7.html)
EA (1) EA202092581A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20077518A (cg-RX-API-DMAC7.html)
ES (1) ES2947446T3 (cg-RX-API-DMAC7.html)
FI (1) FI3788045T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230909T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062277T2 (cg-RX-API-DMAC7.html)
IL (1) IL278416B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200277B1 (cg-RX-API-DMAC7.html)
LT (1) LT3788045T (cg-RX-API-DMAC7.html)
MA (1) MA52492B1 (cg-RX-API-DMAC7.html)
MD (1) MD3788045T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011622A (cg-RX-API-DMAC7.html)
MY (1) MY205388A (cg-RX-API-DMAC7.html)
PE (1) PE20210414A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551848A1 (cg-RX-API-DMAC7.html)
PL (1) PL3788045T3 (cg-RX-API-DMAC7.html)
PT (1) PT3788045T (cg-RX-API-DMAC7.html)
RS (1) RS64418B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010913PA (cg-RX-API-DMAC7.html)
SI (1) SI3788045T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300203T1 (cg-RX-API-DMAC7.html)
UA (1) UA128160C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019213445A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007487B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3788045T3 (pl) * 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
BR112021009610A2 (pt) 2018-11-20 2021-08-10 Sironax Ltd composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
ES3043457T3 (en) * 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
SMT202600151T1 (it) * 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AU2020391425A1 (en) * 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
EP4200281A4 (en) * 2020-08-18 2024-09-25 Hutchison Medipharma Limited PYRIMIDINONE COMPOUNDS AND THEIR USES
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2022237890A1 (zh) * 2021-05-14 2022-11-17 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
US20240425524A1 (en) * 2021-10-27 2024-12-26 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof
KR20230100646A (ko) * 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
JP2025510009A (ja) * 2022-02-28 2025-04-14 シロナックス リミテッド. Rip1調節物質、その調製、及び使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3256467A1 (en) 2015-02-13 2017-12-20 GlaxoSmithKline Intellectual Property Management Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
RU2716136C2 (ru) * 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
WO2017064217A1 (en) 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
WO2020001420A1 (zh) 2018-06-26 2020-01-02 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
JP7045526B2 (ja) 2018-11-02 2022-03-31 中国科学院上海薬物研究所 Rip1キナーゼを阻害する複素環状アミド及びその使用
ES3043457T3 (en) 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
SMT202600151T1 (it) * 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
US20240217958A1 (en) 2024-07-04
SI3788045T1 (sl) 2023-07-31
HRP20230909T1 (hr) 2023-12-08
HUE062277T2 (hu) 2023-10-28
SG11202010913PA (en) 2020-12-30
WO2019213445A1 (en) 2019-11-07
US10975064B2 (en) 2021-04-13
EP3788045B1 (en) 2023-05-31
ECSP20077518A (es) 2021-03-31
CL2020002840A1 (es) 2021-04-16
CR20200582A (es) 2021-04-14
RS64418B1 (sr) 2023-09-29
JOP20200277A1 (ar) 2020-11-03
LT3788045T (lt) 2023-06-26
AU2019262142B2 (en) 2024-11-21
MD3788045T2 (ro) 2023-09-30
DOP2020000197A (es) 2021-04-30
EA202092581A1 (ru) 2021-04-08
JOP20200277B1 (ar) 2024-04-18
ES2947446T3 (es) 2023-08-09
CY1126152T1 (el) 2023-11-15
US20210214347A1 (en) 2021-07-15
ZA202007487B (en) 2023-01-25
MX2020011622A (es) 2021-02-17
IL278416A (cg-RX-API-DMAC7.html) 2020-12-31
MY205388A (en) 2024-10-19
JP2021523225A (ja) 2021-09-02
CO2020015153A2 (es) 2021-03-08
KR20210006407A (ko) 2021-01-18
PH12020551848A1 (en) 2021-06-28
MA52492A (fr) 2021-03-10
SMT202300203T1 (it) 2023-09-06
JP7379467B2 (ja) 2023-11-14
PL3788045T3 (pl) 2023-10-09
BR112020022423A2 (pt) 2021-02-02
PT3788045T (pt) 2023-06-26
IL278416B2 (en) 2023-12-01
UA128160C2 (uk) 2024-04-24
EP3788045A1 (en) 2021-03-10
AU2019262142A1 (en) 2020-11-26
US11919890B2 (en) 2024-03-05
CN112384510A (zh) 2021-02-19
FI3788045T3 (fi) 2023-06-28
US20190337934A1 (en) 2019-11-07
CA3099018A1 (en) 2019-11-07
MA52492B1 (fr) 2023-09-27
IL278416B1 (en) 2023-08-01
DK3788045T3 (da) 2023-06-26
CN112384510B (zh) 2025-06-13
PE20210414A1 (es) 2021-03-04

Similar Documents

Publication Publication Date Title
KR102808215B1 (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
KR102824407B1 (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
JP7379467B2 (ja) Rip1阻害剤化合物並びにそれを製造及び使用するための方法
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
EP4025575B1 (en) Rip1 inhibitory compounds and methods for making and using the same
EP4126864A1 (en) Rip1k inhibitors
AU2021300831A1 (en) RIP1k inhibitors
HK40041257A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40041257B (en) Rip1 inhibitory compounds and methods for making and using the same
HK40091929A (en) Rip1 inhibitory compounds and methods for making and using the same
EA046406B1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220413

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240627

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250319

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250618

End annual number: 3

Start annual number: 1

PG1601 Publication of registration